Harpoon Therapeutics Inc (DELISTED) (HARP:DL)
23.01
0.00 (0.00%)
USD |
NASDAQ |
Mar 11, 16:00
Harpoon Therapeutics Research and Development Expense (Quarterly): 12.32M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 12.32M |
| June 30, 2023 | 12.20M |
| March 31, 2023 | 15.16M |
| December 31, 2022 | 18.95M |
| September 30, 2022 | 20.98M |
| June 30, 2022 | 20.65M |
| March 31, 2022 | 20.82M |
| December 31, 2021 | 20.66M |
| September 30, 2021 | 16.97M |
| June 30, 2021 | 18.27M |
| March 31, 2021 | 16.22M |
| December 31, 2020 | 15.06M |
| Date | Value |
|---|---|
| September 30, 2020 | 13.06M |
| June 30, 2020 | 11.92M |
| March 31, 2020 | 12.52M |
| December 31, 2019 | 12.71M |
| September 30, 2019 | 9.533M |
| June 30, 2019 | 9.971M |
| March 31, 2019 | 9.382M |
| December 31, 2018 | 8.717M |
| September 30, 2018 | 5.967M |
| June 30, 2018 | 6.151M |
| March 31, 2018 | 5.533M |
| December 31, 2017 | 4.79M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
9.533M
Minimum
Sep 2019
20.98M
Maximum
Sep 2022
15.44M
Average
15.11M
Median
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co Inc | 3.992B |
| Axonics Inc | 11.06M |
| Johnson & Johnson | 3.542B |
| Boston Scientific Corp | 366.00M |
| Ambrx Biopharma Inc (DELISTED) | 16.27M |